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A questionnaire survey was conducted by the Epidemiology Working Group of the European Cervical Cancer Screening Network,
and the International Agency for Research on Cancer, IARC, between August and December 2003 in 35 centres in 20 European
countries with reliable cervical cancer incidence and/or mortality data in databanks held at IARC and WHO. The questionnaire was
completed by 28 centres from 20 countries. The final tables included information on 25 centres from 18 countries. Six countries had
started screening in the 1960s, whereas 10 countries or regions had started at least a pilot programme by 2003. There were six
invitational and nine partially invitational programmes, the rest employing opportunistic screening only. Recommended lifetime
number of smears varied from seven to more than 50. Coverage of smear test within the recommended screening interval (usually 3
or 5 years) was above 80% in three countries. Screening registration took place in 13 programmes. Eight programmes reported the
rates of screen-detected cervical cancers and precursor lesions. There was wide variation in the CIN3 detection rates. International
guidelines and quality assurance protocols are useful for monitoring and evaluating screening programmes systematically. Our survey
indicated that the recommendations as currently given are met in only few European countries. Health authorities need to consider
stronger measures and incentives than those laid out in the current set of recommendations.
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BACKGROUND
Organised screening programmes for cervical cancer using Pap
smears have been shown to be effective in decreasing mortality and
incidence from the disease (Fidler et al, 1968; Hakama and
Ra ¨sa ¨nen-Virtanen, 1976; Hakama, 1982; Day, 1986; La ¨a ¨ra ¨ et al,
1987; Lynge, 2000). Opportunistic or nonorganised screening also
decrease cervical cancer rates, although not to the extent of
organised programmes (Magnus and Langmark, 1986; Lynge et al,
1989; Nieminen et al, 1999). One problem with nonorganised
screening is that it may not adequately cover the population
targeted, sometimes missing those at highest risk (Coleman et al,
1993a).
If clinical and diagnostic quality are not monitored and
evaluated systematically, as in nonorganised screening, there are
also concerns that adverse effects may become more common
(Council of the EU, 2003). The goal of an organised programme,
along with achieving reasonable effectiveness, is that potential
adverse effects are minimised while screening-related improve-
ments in the quality of life maximised. Overuse of services can be
prevented and a complete evaluation can be implemented only
within the framework of an organised programme.
The European Union (EU) currently recommends that cancer
screening should only be offered on a population basis in
organised screening programmes, with quality assurance at all
levels (Council of the EU, 2003). There are also some more detailed
recommendations describing the implementation, registration,
monitoring, training, compliance, and introduction of novel tests
of organised cancer screening programmes (Advisory Committee
on Cancer Prevention, 2000; Sankila et al, 2000; Council of the EU,
2003). Managerial guidelines have also been published by the
WHO, and there are guidelines in several areas or individual
countries describing how to organise a programme.
In Europe, there are wide variations in the organisation of
cervical cancer screening activities (Linos et al, ed., 2000). The
present study aims to describe the main policy and organisational
elements in cervical cancer screening programmes in many
European countries, and compare them with the EU and other
recommendations.
MATERIALS AND METHODS
The study is based on a questionnaire survey, collected in late 2003
from 20 European countries within the framework of a collabora-
tive research project of the European Cervical Cancer Screening
Network (ECCSN), funded by the Europe Against Cancer
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yprogramme, and the International Agency for Research on Cancer
(IARC), Lyon. The questionnaire survey was conducted in
August–December 2003. The present report summarises the
current and historical screening situation in Europe. However, as
these data were also collected within the framework of interpreting
long-term cervical cancer trends at a population level, only
European countries or regions for which cervical cancer mortality
and/or incidence data met eligibility criteria for the assessment of
cervical cancer trends were included.
More specifically, countries or regions were selected according
to the following criteria:
(1) Countries with mortality data available for more than 10 years
(not necessarily consecutively) in the WHO mortality database
up to 2000, and where ‘Not Otherwise Specified’ uterine cancer
deaths accounted for less than 25% of all uterine cancer deaths
(these NOS uterine cancer deaths can be redistributed based
on the age-specific proportion of registered cervix and corpus
cancer deaths (Arbyn and Geys 2002; Bray et al, 2002)).
(2) Countries without mortality data meeting the above quality
criteria, but for which cervical cancer incidence data of
sufficient quality was available, either nationwide, or within a
specific region. Criteria for data quality consisted of cancer
registry-based incidence data published in at least three
consecutive volumes of ‘Cancer incidence in five continents’
from IARC (Parkin et al, 1992, 1997, 2002).
Countries meeting criteria for mortality data were: the Czech
Republic, Denmark, Estonia, Finland, Hungary, Iceland, Lithuania,
Luxembourg, the Netherlands, Norway, Switzerland, and the UK.
Countries and regions meeting criteria for incidence data were:
France (regional data only, from eight regions: Bas-Rhin, Calvados,
Doubs, Herault, Ise ´re, Limousin, Somme, Tarn); Germany (Saar-
land only); Italy (from four regions: Florence, Parma, Ragusa,
Varese, and two cities: Genova, Torino); Poland (Cracow only);
Slovakia, Slovenia, Spain (from four regions: Catalonia, Granada,
Murcia, Navarra), and Sweden. For countries with only regional
incidence data, region-specific information on cervical cancer
screening was requested.
Emphasis was placed on collecting both current and historical
information on the following:
 Screening policy: Year of programme initiation; target age range
of screening; screening interval for women with normal results;
financial cost of the smear to the women;
 Organisational issues: Whether all women in the target
population are invited, or only those without a recent smear;
the manner in which women are invited (personally or
otherwise); the data source from which invitations are drawn;
whether invitations and visits are centrally registered on an
individual basis; if there had been, historically, important
changes in the screening organisation;
 Process and performance measures: Invitational and geographi-
cal coverage of the programme or policy; screening attendance;
proportion of women tested at least once within the recom-
mended interval; availability of data on detection rates of
histologically confirmed cancerous or precancerous findings, by
severity of lesions.
We also enquired as to how estimates on screening parameters
were collected and calculated in order to assess the reliability of the
reported information, and we also searched for all published
information on the programmes.
Different organisational definitions affect the applicability of the
concept, while invitational coverage can apply only among
invitational programmes. Another measure of coverage, the
proportion of the target population subject to formal programme
or policy (van Ballegooijen et al, 2000), was included in the tables.
In addition, proportion of women tested at least once within the
recommended interval was used. The latter attendance rate is a
combined measure of invitational coverage and related attendance,
plus noninvitational smear-taking activity.
In addition to smears taken within programmes, spontaneous
smears taken outside the programme were reported by several
centres. Lack of information prevented their inclusion in detail in
all performance measures. For those programmes, which regis-
tered smears, proportions of women tested at least once during the
recommended interval could be calculated from the register-based
source. For those programmes that registered only the invitational
programme, corresponding estimates were based usually on
questionnaire surveys where the reliability of the information
may be limited due to reporting and selection biases. Owing to the
lack of information, calculations could not be carried out for some
other relevant time windows, such as smears during the last 10
year period.
The 2003 survey was sent to 35 centres in 20 countries and was
completed by 28 centres from 20 countries. In the returned
questionnaires from Estonia, Cracow (Poland), and Somme
(France), it was reported that no ‘organised programme or
otherwise defined screening policy for cervical cancer’ existed
and there were no responses to further questions on screening
activities. Therefore, these countries/regions were not included in
the detailed tables. All the questionnaire information was managed
in a database at IARC.
RESULTS
Details of screening policy are included in Table 1, irrespective of
whether organised, spontaneous, or nonspecific screening pro-
grammes were in place. Six countries (the Czech Republic,
Denmark, Finland, Iceland, Luxembourg, Sweden) reported having
started screening in the 1960s, whereas 10 other countries or
regions (Hungary, Lithuania, Norway, Slovenia, Bas-Rhin, Doubs,
Isere, Genova, Parma, Torino) had started at least a pilot by 2003.
There were large differences in target age range and interval.
Recommended lifetime number of smears varied from seven
(Finland, Lithuania, Netherlands, Isere) to more than 50 (Lux-
embourg, Germany).
The cost covered by the screened women varied widely. In most
of the regions (17 out of 25; 68%), screening was free of charge for
the women but in several programmes payment practices varied
even within the programme, depending on the area or mode of
screening activity.
Six countries/regions had invitational programmes (Finland,
Hungary, the Netherlands, Ise ´re, Parma, Torino), whereas nine
countries/regions (Denmark, Iceland, Norway, Slovenia, Swdeden,
United Kingdom, Bas-Rhin, Doubs, Florence) invited only those
women who had not had a smear (usually opportunistic) recently
or within the recommended interval (Table 2). The other regions
did not invite women, but screening was offered mainly at the
occasion of a visit to a general practitioner or gynaecologist.
All of the six fully invitational programmes also had a
centralised national or regional screening registration database
arranged on an individual basis. Five of these registers included
only the invitational programme and one (the Netherlands)
included any smears. From among the programmes with partial
invitations, two programmes (Denmark, Sweden) did not have a
centralised national registration unit. The rest of the national
programmes with a partial invitational activity reported a central
national registration system, and these registers aimed to include
all smears, whether taken after invitation or otherwise. Of the
10 countries/regions with opportunistic screening policies,
eight were without screening registration and two had partial
registration.
Smear test coverage above 80% of the target population during
the recommended screening interval was reported in three national
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75–80% in three countries (Denmark, Iceland, the Netherlands).
A total of 11 programmes reported collection of information on
histologically confirmed lesions (Table 2). Six of these pro-
grammes reported detection rates by grade of the histological
finding (Finland, Iceland, Norway, Bas-Rhin, Florence, Torino)
and one country (the Netherlands) did not separate invasive
cancers from the CIN3 (Table 3). Histological information was also
reported from Catalonia, a region with opportunistic activity only.
No published routine monitoring information was available for
other programmes. There was a wide variability in the rates
between the seven programmes from 0.008 to 0.04% for invasive
cancer, from 0.06 to 0.50% for CIN3, and from 0.12 to 0.8% for
CIN1-2. CIN3:invasive cancer detection ratios ranged from 1.5
to 12.
DISCUSSION
The European Union has currently recommended that cancer
screening should only be offered on a population basis in
organised screening programmes, with quality assurance at all
levels (Council of the EU, 2003). There are also more detailed
recommendations that are valuable in relation to organisational
aspects (Advisory Committee on Cancer Prevention, 2000; Council
of the EU, 2003). The present questionnaire-based survey indicates
that these recommendations are met in only a few European
countries.
The most serious inadequacies relate, according to our survey,
to: (1) low or inadequate coverage of the screening test within the
populations targeted; (2) shortcomings in routine registration,
evaluation, and monitoring; and (3) excessive numbers of lifetime
smears recommended. There also exist relatively short screening
intervals that are not justified as present knowledge of the natural
history of cervical cancer, particularly on the duration of
precancerous stage. Such aspects as payment strategies, possibly
affecting attendance, varied greatly, indicating a potential for
inequality.
Incidence and mortality rates from cervical cancer can be
decreased by at least 80% by means of screening. This has been
shown from follow-up studies of women screened negative (Day,
1986), cohort follow-up studies among screened women (Fidler
et al, 1968; Hakama and Ra ¨sa ¨nen-Virtanen, 1976; Lynge, 2000),
and population-based follow-up studies (Hakama 1982; Day, 1986;
Table 1 Screening policy in the 18 European countries
Country/region
Onset of screening
programme or policy
Age range targeted
(since year)
Recommended screening
interval
Charge of smear for
the women
Recommended
number of
lifetime smears
Czech Republic 1966 Not specified (1966) 1 year Free Not specified
Denmark 1967 23–59 (1986) 3 years (some counties 5 years in
445 or 50)
Free 13
Finland 1963 30–60 (1993) 5 years Free 7
Hungary 2003, pilot 1997 25–65 (1997) 3 years, after one negative smear Free 15
Iceland 1964 20–69 (1988) 2 years Partial contribution (31
USD)
25
Lithuania 2001 30–60 (2001) 5 years Free or partial
contribution (5 euro)
7
Luxembourg 1962 15+ (1990) 1 year Free B70
Netherlands 1980 30–60 (1996) 5 years Free 7
Norway 1995, pilot 1992 (programme
in one county in 1959–1977)
25–69 (1992) 3 years Partial contribution 15
Slovakia — (intention) 25–64 (—) 3 years Free 14
Slovenia 2003 (1955 opportunistic) 20–64 (2002) 3 years Free 15
Sweden 1967–1973 in different
counties, Gothenburg 1977
23–60 (1999) 3 years in ages 23–50 years; 5
years in ages 51–60 years
Complete contribution
in most counties; free
or partial in some
counties
12
Switzerland No data 18–69 (—) 3 years Partial contribution 18
UK 1988 20–64 (1988, under
review)
3–5 years (currently 3 years in ages
25–49 years and 5 years in ages
50–64 years)
Free 10–17 (12)
France
Bas-Rhin 1994 25–65 (1990) 3 years Partial contribution 14
Doubs 1993 20–65 (1993) 3 years (after two normal exams
with 1 year interval)
Reimbursement 17
Ise ´re 1990 50–69 (1990) 3 years Free 7
Germany
Saarland 1971 20–85+ (1982) 1 year Free B65
Italy
Florence 1982 25–64 (1995) 3 years Free 14
Genova 1992 25–64 (1992) 3 years Free 14
Parma 1998 25–64 (1998) 3 years Free 14
Ragusa No data 25–64 (1996) 3 years Free 14
Torino 1992 25–64 (1992) 3 years Free 14
Varese No data 25–64 (1996) 3 years Free 14
Spain
Catalonia No data 20–64 (1993) 3–5 years: initially two smears 1
year apart. Then, 3 years in ages
20–34 years and 5 years in ages
35–64 years
Free or partial
contribution
12
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Country/region
Are women in
the target
population
invited
personally to
participate?
How women are
invited/smears
offered
Source of personal
invitations
Is screening registered
on an individual basis?
Information
available on
screen-detected
histological
findings? Remarks
Czech Republic No Opportunity — No No
Denmark Yes, only women
without a recent
smear
Letter or opportunity Population, pathology
and health insurance
registries
No national registration.
Varies between counties,
most have all smears and
histology in the county
pathology register
No Organised screening
was introduced
gradually county-wise.
Information on
screening and
histological findings can
be collected as a
research activity
Finland Yes Letter Population registry Yes, centrally, invitational
programme
Yes Organised screening
introduced gradually
during 1963–1970;
invitational coverage
almost complete since
1971
Hungary Yes Letter Social security register
and health insurance
funds
Yes, centrally, invitational
programme
No
Iceland Yes, only women
without a recent
smear
Letter or opportunity Population registry Yes, centrally, all Yes Computerised call-
recall system from
1964. About 70% of
smears in 2000 were
from the invitational
programme
Lithuania No (yes in some
regions)
Opportunity,
announcements, mass
media
Health service registers Yes, centrally (in 10 out of
60 regions), invitational
programme
Yes
Luxembourg No Opportunity — Yes, most of them at the
national health laboratory
Yes Reorganisations in 1980
and 1990
Netherlands Yes Letter Population registry Yes, both centrally and
regionally, all
Yes
Norway Yes, only women
without a recent
smear
Letter or opportunity Population registry Yes, centrally, all Yes
Slovakia No (yes in some
districts)
Letter or opportunity Health service registers No No
Slovenia Yes, only women
without a recent
smear
Letter or opportunity Population and health
service registers
Yes, centrally, all Yes (under
construction)
Sweden Yes, only women
without a recent
smear
Letter or opportunity Population registry Yes, regionally, all. A central
register under construction
Yes (under
construction)
Switzerland No Opportunity — — No
UK Yes, only women
without a recent
smear
Letter or opportunity Health services register Yes, centrally and regionally,
all
Yes Computerised call-
recall in 1988. Target
incentive payments to
GPs since 1990.
National coordination
and quality assurance
introduced in 1995
France
Bas-Rhin Yes, only women
without a recent
smear
Letter or opportunity Health service register Yes, regionally, all Yes
Doubs Yes, only women
without a recent
smear
Letter and/or campaign Social security register Yes, regionally, all No data
Ise ´re Yes Letter Social security register Yes, regionally, invitational
programme
No data Pap smear screening in
connection with breast
cancer screening
Germany
Saarland No Smears offered through
health insurance
scheme
—N o N o
Italy
Florence Yes, only women Letter or opportunity Population registry Yes, regionally, all Yes
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Canada (British Columbia) (Anderson et al, 1988) and in Finland
and Iceland (La ¨a ¨ra ¨ et al, 1987; Sigurdsson, 1999; Anttila and La ¨a ¨ra ¨,
2000). In the other Nordic countries, decreases of between 40 and
60% have been reported (Sigurdsson, 1999), while the reduction
tends to be of a somewhat lower order of magnitude in other
regions and countries (Coleman et al, 1993b; Beral et al, 1994).
Information is variable and often very limited, however, concern-
ing the screening activities or incidence or death rates before the
assumed time that screening started. These data as well as the
without a recent
smear
Genova No Opportunity — No No
Parma Yes Letter Population and health
service register
Yes, regionally, invitational
programme
Yes
Ragusa No Opportunity — No No
Torino Yes Letter Population registry Yes, regionally, invitational
programme
Yes
Varese No Opportunity — No No Screening campaigns in
the past within part of
the area
Spain
Catalonia No Opportunity — No Yes
Table 2 (Continued)
Country/region
Are women in
the target
population
invited
personally to
participate?
How women are
invited/smears
offered
Source of personal
invitations
Is screening registered
on an individual basis?
Information
available on
screen-detected
histological
findings? Remarks
Table 3 Process and performance values in screening for cervical cancer in the 18 European countries
Detection rate (%)
Country/region
Population subject to
formal programme (in
ages 25–64 years
unless specified)
Women screened within recommended
interval (%), any smears included (in
ages 25–64 years in 2000 unless
specified)
Invasive
(ICC) CIN3 CIN1-2
Czech republic No data No data No data No data No data
Denmark 90% (23–59) 75% (23–59, 1997) No data No data No data
Finland 100% (30–60) 93% (35–64, 1997) 0.01 0.13 0.21
Hungary No data 30% No data No data No data
Iceland 100% 76% within a 3-year interval (25–69) 0.015 0.47 0.27
Lithuania No data No data No data No data No data
Luxembourg No data 39% (1 year, 1999)
a No data No data No data
Netherlands 100% (30–60)
b 77% (30–60, 1997)
b No data 0.35 (incl.
CIN3+)
0.13
Norway 100% 70% 0.04
c 0.50
c 0.79
c
Slovakia No data No data No data No data No data
Slovenia 31% in 2000 70% No data No data No data
Sweden 100%
b 83 (23–59; 1997)
b No data No data No data
Switzerland No data No data
d No data No data No data
UK 100% 83% No data No data No data
France
Bas-Rhin No data 69%
e 0.05 0.35 0.73
Doubs 88% 450% No data No data No data
Ise ´re No data 69% (50–69, 1996) No data No data No data
Germany
Saarland 90%
b 50% per year (20+; 1996); 80% within 3 years
b No data No data No data
Italy
Florence 100% 73% 0.008 0.13 0.12
Genova No data 53%
f No data No data No data
Parma 100% 66% No data No data No data
Ragusa No data 53%
f No data No data No data
Torino 100% 474% 0.011 0.09 0.14
Varese No data 53%
6 No data No data No data
Spain
Catalonia No data No data 0.04 0.06 0.8
aFrom Scheiden et al (2000).
bFrom Van Ballegooijen et al (2000); whole Germany.
cIn 1998, from The Cancer Registry of Norway (2001).
d80% ever-screened (18–75; 1997).
eFrom Schaffer et al (2000).
fNo regional data. Italian national estimate 1999/2000.
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suggest that meaningful additional decreases in the cervical cancer
rates are still possible. It is important therefore to utilise the
available data continually to monitor cervical incidence and
mortality rates in these populations.
The current data were obtained from areas covered by long-
standing cancer registries. Therefore, they may not be representative
of the entire European situation. Frequently there is a link between
pilot programmes for cervical cancer screening and cancer
registration, given the utility of the latter using planning and
screening evaluation. For example in France, all three existing
regional programmes were in areas with a cancer registry considered
to satisfy minimal quality assurance prerequisites. The study may
thus overestimate the presence of organised programmes.
The reported CIN3 detection rates varied eight-fold. This can be
expected to result in t differences in related treatment rates. These
differences are apparently not explained by differential screening
intervals or age ranges. Variation in the background risk could
provide a partial explanation, but the variations in cancer to CIN3
detection ratios suggest that differential diagnostic and registration
criteria may play a major role.
The disadvantages of cancer screening include: anxiety among
those screened positive or treated for a lesion, complications,
potential of unnecessary medical interventions (e.g. among false-
positives), overtreatment of questionable or nonprogressive
abnormalities, costs incurred, longer morbidity for cases whose
prognosis is unaltered, and also false reassurance that can result in
delayed presentation or investigation of symptoms for persons
with false-negative test results (Hakama, 1991; Bennetts et al, 1995;
Lauver et al, 1999; Peters et al, 1999; Rogstad, 2002; Idestrom et al,
2003). Quality-of-life and potential adverse aspects should be
included in the evaluation of the screening programmes. These
also represent important aspects to be considered for any potential
new screening techniques to be implemented in programmes.
Several Eastern European countries, which had established
cancer registries, were included in this questionnaire study, but
most had not implemented an organised screening programme. It
should be noted that mortality rates are uniformly increasing in
several countries in this region (Beral et al, 1994; IARC, 2002.
Whenever possible, cancer registries should be involved in the
planning and monitoring of screening programmes. Availability of
local resources needs to be carefully taken into account. Given
limited screening resources, the programme should be started in a
few age groups, with high coverage being prioritised.
In general, there are large variations in European cervical cancer
screening policies and in the organisation of programmes. Limited
details are available on process and performance measures, and
their correlation with effectiveness is not known. In particular,
registration, monitoring, and evaluation are deficient. The EU
Council recommendation states that ‘subsequent monitoring and
data collection on the extent to which the proposed measures are
working effectively need to be arranged for the next 3-year period’.
Decision-makers and health-care service providers need to
consider stronger measures and incentives than the current
recommendations in order to deliver successful cervical cancer
control in Europe.
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